Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.
DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.
Biocompatibility restrictions have limited the use of magnetic nanoparticles for magnetic hyperthermia therapy to iron oxides, namely magnetite (Fe3O4) and maghemite (gamma-Fe2O3). However, there is yet another magnetic iron oxide phase that has not been considered so far, in spite of its unique magnetic properties: epsilon-Fe2O3. Indeed, whereas Fe(3)O(4)and gamma-Fe(2)O(3)have a relatively low magnetic coercivity, epsilon-Fe(2)O(3)exhibits a giant coercivity. In this report, the heating power of epsilon-Fe(2)O(3)nanoparticles in comparison with gamma-Fe(2)O(3)nanoparticles of similar size (similar to 20 nm) was measured in a wide range of field frequencies and amplitudes, in uncoated and polymer-coated samples. It was found that epsilon-Fe(2)O(3)nanoparticles primarily heat in the low-frequency regime (20-100 kHz) in media whose viscosity is similar to that of cell cytoplasm. In contrast, gamma-Fe(2)O(3)nanoparticles heat more effectively in the high frequency range (400-900 kHz). Cell culture experiments exhibited no toxicity in a wide range of nanoparticle concentrations and a high internalization rate. In conclusion, the performance of epsilon-Fe(2)O(3)nanoparticles is slightly inferior to that of gamma-Fe(2)O(3)nanoparticles in human magnetic hyperthermia applications. However, these epsilon-Fe(2)O(3)nanoparticles open the way for switchable magnetic heating owing to their distinct response to frequency.